ClinicalTrialsFinder
RecruitingNCT04961593

PK/PD of Caspofungin in Children Severe Infection

Pharmacokinetics and Pharmacodynamics of Caspofungin in Children Severe Infection

Sponsor

Children's Hospital of Fudan University

Enrollment

60 participants

Start Date

Oct 1, 2022

Study Type

OBSERVATIONAL

Conditions

PharmacokineticsInfection, Fungal

Summary

Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver dysfunction. There is little metabolism of caspofungin through the kidney and continuous renal replacement therapy and renal function have little influence on the pharmacokinetics of caspofungin. The study aim to investigate PK/PD of caspofungin in children with specific pathophysiological conditions, such as liver insufficiency, hypoproteinemia, ECMO treatment, or sepsis.

Eligibility

Min Age: 3 MonthsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study examines how caspofungin — an antifungal medication — works in the bodies of critically ill children, to understand the best dosing for young patients in intensive care. You may be eligible if: - Your child is between 3 months and 18 years old - Your child is admitted to a pediatric intensive care unit (PICU) - Your child is already receiving caspofungin You may NOT be eligible if: - Informed consent has not been signed - Your child is participating in another clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCaspofungin

For children 3 months of age, the recommended dose is 70 mg/m2 for load and then 50 mg/m2 for maintenance, intravenous injection, once daily up to 5 days.

Locations(2)

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04961593

Related Trials

Pharmacokinetics of Kava and Kratom Alone and in Combination

NCT075834071 location

Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies

NCT046697171 location

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT075601501 location

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT074222855 locations

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT065007931 location